Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non Operating Income: 2010-2025

Historic Non Operating Income for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$26.0 million.

  • Lineage Cell Therapeutics' Non Operating Income fell 3194.87% to -$26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.3 million, marking a year-over-year decrease of 1763.82%. This contributed to the annual value of $2.9 million for FY2024, which is 99.59% up from last year.
  • Lineage Cell Therapeutics' Non Operating Income amounted to -$26.0 million in Q3 2025, which was down 145.33% from -$10.6 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Non Operating Income registered a high of $5.6 million during Q1 2021, and its lowest value of -$26.0 million during Q3 2025.
  • Moreover, its 3-year median value for Non Operating Income was $103,000 (2024), whereas its average is -$2.8 million.
  • Data for Lineage Cell Therapeutics' Non Operating Income shows a peak YoY increase of 2,193.20% (in 2025) and a maximum YoY decrease of 11,359.57% (in 2025) over the last 5 years.
  • Over the past 5 years, Lineage Cell Therapeutics' Non Operating Income (Quarterly) stood at $229,000 in 2021, then increased by 20.96% to $277,000 in 2022, then skyrocketed by 227.44% to $907,000 in 2023, then skyrocketed by 105.07% to $1.9 million in 2024, then plummeted by 3,194.87% to -$26.0 million in 2025.
  • Its Non Operating Income stands at -$26.0 million for Q3 2025, versus -$10.6 million for Q2 2025 and $2.4 million for Q1 2025.